# Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 Canonical URL: https://biopharmsignal.com/news/ADAP/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025 Ticker: ADAP Company: Adaptimmune Therapeutics plc Source: Adaptimmune Therapeutics plc Published: 2025-01-30 21:00 EST Original Source URL: https://www.adaptimmune.com ## Summary

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotec ## Article Body Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, NY Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. EST Webcast link: https://wsw.com/webcast/guggen2/adap/1969770 This event can also be accessed by visiting 'Events', under the 'News Center' tab, in the 'Investors & Media' section of Adaptimmune's website at www.adaptimmune.com. Following the event, a replay of the presentation will be made available. About Adaptimmune Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. Adaptimmune Contact Investor Relations Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations T : +1 215 825 9310 M : +1 215 460 8920 Juli.Miller@adaptimmune.com Media Relations Dana Lynch, Senior Director of Corporate Communications M: +1 267 990 1217 Dana.Lynch@adaptimmune.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239017 SOURCE Adaptimmune Therapeutics PLC ## Recent Company News - 2025-11-17 12:30 EST — [Adaptimmune Announces Changes to Board and Executive Leadership Team](https://biopharmsignal.com/news/ADAP/adaptimmune-announces-changes-to-board-and-executive-leadership-team) — Source: Adaptimmune Therapeutics plc - 2025-10-20 11:40 EST — [Adaptimmune Announces Delisting from Nasdaq](https://biopharmsignal.com/news/ADAP/adaptimmune-announces-delisting-from-nasdaq) — Source: Adaptimmune Therapeutics plc - 2025-08-13 11:30 EST — [Adaptimmune Reports Q2 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADAP/adaptimmune-reports-q2-financial-results-and-provides-business-update) — Source: Adaptimmune Therapeutics plc - 2025-07-28 11:30 EST — [Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds](https://biopharmsignal.com/news/ADAP/adaptimmune-announces-entry-into-definitive-agreement-for-sale-of-tecelra-lete-cel-afami-cel-and-uza-cel-cell-therapies-to-us-worldmeds) — Source: Adaptimmune Therapeutics plc - 2025-05-13 11:30 EST — [Adaptimmune Reports Q1 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADAP/adaptimmune-reports-q1-financial-results-and-provides-business-update) — Source: Adaptimmune Therapeutics plc ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)